Advances in antibody-based strategies for targeting cancer-associated glycopeptide antigens.

The development of tumor-targeting antibodies has progressed tremendously over the past few decades, yet improving tumor selectivity and efficacy remains a challenge. Among tumor-associated antigens, tumor-associated carbohydrate antigens (TACAs) hav…

Preview only. Read the full abstract at the source